Skip to main content
S&P 5007,775.90-0.55%DOW50,981.24-1.05%NASDAQ27,420.52-0.65%BTC$82,984.00-3.81%ETH$2,559.16-5.73%GOLD$4,128.20-1.41%OIL$89.81+0.41%
Smart Investors Daily
SID Premium
TV

NASDAQ · TVGN

Tevogen Bio Holdings Inc.

Healthcare · Biotechnology

$6.49

Up+$0.41 (+6.32%)

Updated Oct 7, 2026, 3:29 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
85.1M
P/E ratio
-2.7
Dividend yield
0.00%
52-week range
$3.64 – $39.50
Volume
2.84K
Avg. volume
795.94K

Price performance · TVGN

TVGN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

TVGN closed at $6.49 after 20 trading sessions, down 11.46% for the selected period.

Last close
$6.49
Period change
-11.46%
Period low
$6.49
Period high
$7.85
Daily close
View OHLC price history
TVGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$6.56$6.56$6.4606$6.492.84K
Oct 5, 2026$6.898$6.97$6.57$6.603.48K
Oct 2, 2026$6.5869$7.01$6.5869$6.981.62K
Oct 1, 2026$6.35$6.985$6.35$6.726.54K
Sep 30, 2026$6.57$7.23$6.57$6.621.93K
Sep 29, 2026$6.96$7.065$6.75$6.751.38K
Sep 28, 2026$7.44$7.50$6.76$6.7615.63K
Sep 25, 2026$7.70$7.70$7.25$7.255.57K
Sep 24, 2026$7.44$7.85$7.04$7.852.93K
Sep 22, 2026$7.58$7.81$7.4301$7.812.79K
Sep 21, 2026$7.81$7.81$7.43$7.431.78K
Sep 18, 2026$7.43$7.81$7.43$7.8120.47K
Sep 17, 2026$7.3228$7.71$7.3228$7.712.45K
Sep 16, 2026$7.0401$7.80$7.0401$7.802.76K
Sep 15, 2026$7.57$7.77$7.52$7.752.61K
Sep 14, 2026$7.12$7.85$7.12$7.5115.4K
Sep 11, 2026$6.97$7.90$6.97$7.3672.67K
Sep 10, 2026$7.2644$7.29$7.0378$7.292.49K
Sep 9, 2026$7.215$7.34$7.10$7.344.08K
Sep 8, 2026$7.32$7.33$6.96$7.333.17K

Latest TVGN news

The latest Smart Investors Daily articles mentioning TVGN.

Stock researchCompany · Overview

TVGN research

Overview

Company profile and research snapshot.

Company profile

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TVGN recent ratings
DateFirmRatingTarget
Mar 4, 2026D. Boral CapitalHold—
Mar 3, 2026D. Boral CapitalBuy—
Nov 20, 2025D. Boral CapitalBuy—
Sep 4, 2025D. Boral CapitalBuy—
Aug 18, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

Both previously disclosed Nasdaq compliance matters are now closedWARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”)on September 29, 2026, confirming that the Company ha

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By